Are AI and Blockchain Shaping D-Wave's Next Growth Phase?

D-Wave highlighted progress in two emerging use cases: blockchain and AI. Its quantum-classical blockchain testNet is live with more than 18,500 sign-ups, and management said its Advantage2 QPU is winning the majority of blocks versus classical nodes. In AI, Shionogi’s drug-discovery project using D-Wave systems reportedly produced a 10x increase in desirable molecules in phase two, while QBTS also remains unprofitable with 2026 and 2027 consensus losses of $0.25 and $0.30 per share.

Analysis

QBTS is trying to reprice itself from a pure “future tech” story into an application-layer platform with two monetizable proof points: quantum-assisted optimization for AI and an early credibility wedge in blockchain. The market should care less about the headline partnerships and more about the sequencing effect: if D-Wave can keep winning benchmark-style contests against classical nodes, it gains a low-cost customer acquisition engine that can convert curiosity into pilots, then pilots into recurring workload. That matters because the stock already trades on a very high multiple, so any durable evidence of differentiated performance can extend multiple support even before revenue inflects.

The second-order winner is not only QBTS but also adjacent ecosystems that can package “quantum-ready” workflows into enterprise software. On the other hand, QUBT and RGTI face a credibility gap relative to D-Wave’s near-term application narrative: their paths depend more on infrastructure buildout and government capital, which tends to move slower and be lumpier. If D-Wave’s benchmarking data is strong, it could widen the valuation spread within quantum, because enterprise buyers usually standardize around the first vendor that can quantify a practical edge, not the one with the cleanest long-term physics thesis.

The main risk is that the recent optimism is front-running proof. These initiatives can remain headline-generating but economically immaterial for several quarters if they do not translate into repeatable contract value, and any benchmark that shows parity rather than advantage would likely compress the multiple quickly. Over a 3-6 month horizon, the key catalyst is whether management can convert these pilots into measurable usage revenue or subscription-like commitments; over 12-24 months, the issue is whether classical AI and optimization tooling closes the gap faster than quantum hardware improves.

Key Decisions for Investors

• Maintain a tactical long QBTS only into benchmark and customer-update catalysts; size modestly and use a 4-8 week horizon, because the setup is asymmetric only if performance data remains clearly above classical nodes.
• Pair trade: long QBTS / short RGTI for 1-3 months if the goal is to express “application traction beats government-funded R&D,” since QBTS has the cleaner near-term commercialization narrative.
• Avoid chasing QUBT here; use rallies to fade unless it can show tangible enterprise revenue conversion, because photonic-inference narratives are more crowded and easier to replicate in public-market sentiment.
• For higher-risk exposure, buy QBTS call spreads 3-6 months out rather than stock outright; the upside is continued multiple expansion, while the downside is a sharp de-rating if benchmarking results are merely average.
• If QBTS fails to publish convincing benchmark deltas within the next 1-2 quarters, rotate out of the name and consider a short on strength, as the current valuation leaves little room for narrative slippage.